Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 14, 2025 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies...
August 22, 2025 08:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...
August 14, 2025 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics Reports Q2 2025 Results and Business Update
May 28, 2025 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...
May 15, 2025 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and...
April 28, 2025 16:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived...
April 15, 2025 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025

PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived...
March 19, 2025 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New...
January 21, 2025 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders

- Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg - -...
November 26, 2024 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...